Staidson Beijing Biopharma Asset Resilience Ratio

Latest as of September 2022: 7.93%

Staidson Beijing Biopharma asset resilience ratio. Staidson Beijing Biopharma (300204) has an Asset Resilience Ratio of 7.93% as of September 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 300204 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥130.40 Million

≈ $19.08 Million USD Cash + Short-term Investments

Total Assets

CN¥1.64 Billion

≈ $240.56 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Staidson Beijing Biopharma (2016–2021)

Asset resilience ratio of Staidson Beijing Biopharma from 2016 to 2021. This chart shows how Staidson Beijing Biopharma's Asset Resilience Ratio has changed over time. Read Staidson Beijing Biopharma debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Staidson Beijing Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 300204 total asset value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥130.40 Million	7.93%
Total Liquid Assets	CN¥130.40 Million	7.93%

Asset Resilience Insights

Limited Liquidity: Staidson Beijing Biopharma maintains only 7.93% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Staidson Beijing Biopharma Industry Peers by Asset Resilience Ratio

Compare Staidson Beijing Biopharma's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Bavarian Nordic CO:BAVA	Biotechnology	10.83%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Staidson Beijing Biopharma Asset Resilience Ratio by Year (2016–2021)

Staidson Beijing Biopharma asset resilience ratio by year from 2016 to 2021. The table below shows the annual Asset Resilience Ratio data for Staidson Beijing Biopharma.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2021-12-31	20.88%	CN¥381.46 Million ≈ $55.82 Million	CN¥1.83 Billion ≈ $267.35 Million	-3.97pp
2020-12-31	24.85%	CN¥461.24 Million ≈ $67.49 Million	CN¥1.86 Billion ≈ $271.62 Million	+10.08pp
2019-12-31	14.77%	CN¥275.00 Million ≈ $40.24 Million	CN¥1.86 Billion ≈ $272.53 Million	-2.58pp
2018-12-31	17.35%	CN¥480.85 Million ≈ $70.36 Million	CN¥2.77 Billion ≈ $405.65 Million	+6.80pp
2017-12-31	10.54%	CN¥277.10 Million ≈ $40.55 Million	CN¥2.63 Billion ≈ $384.64 Million	-15.32pp
2016-12-31	25.86%	CN¥607.86 Million ≈ $88.95 Million	CN¥2.35 Billion ≈ $343.97 Million	--

pp = percentage points

About Staidson Beijing Biopharma

SHE:300204 China Biotechnology

Market Cap

$1.37 Billion

CN¥9.39 Billion CNY

Market Cap Rank

#7349 Global

#1546 in China

Share Price

CN¥17.35

Change (1 day)

+3.64%

52-Week Range

CN¥16.73 - CN¥39.30

All Time High

CN¥61.00